[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ureteral-calculi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ureteral-calculi":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,40,66,96,126,151,179,200,223,243,265],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100635979","risk-factors-and-predictive-model-for-inflammatory-polyps-in-ureteral-stones-100635979",false,"NCT07559721","Risk Factors and Predictive Model for Inflammatory Polyps in Ureteral Stones","Risk Factors and Development of a Predictive Model for Stone-Associated Inflammatory Ureteral Polyps: A Retrospective Cohort Study With Prospective Validation","UROLITH-POLYP","Inclusion Criteria:\n\n* Patients aged 18 years or older undergoing ureteroscopic surgery for ureteral calculi at the First Hospital of Jilin University.\n* Complete clinical and imaging data available.\n\nExclusion Criteria:\n\n* Patients with bilateral ureteral calculi.\n* Patients with preoperative nephrostomy or indwelling ureteral stent.\n* Patients with a history of ureteral or bladder cancer.\n* Patients with congenital ureteral anomalies or previous ureteral surgery.\n* Patients with severe coagulation disorders or contraindications to ureteroscopy.\n* Patients unable to provide informed consent.","ALL","18 Years","80 Years",{"count":21,"type":22},779,"ESTIMATED","OBSERVATIONAL","This is a single-center, observational study including a retrospective cohort and a prospective validation cohort. The study aims to identify independent risk factors for inflammatory ureteral polyps in patients with ureteral calculi and develop a preoperative predictive model. The retrospective part will analyze clinical and imaging data of patients treated at the First Hospital of Jilin University between 2018 and 2025. The prospective part is currently recruiting participants to validate the model. The primary outcome is the intraoperative diagnosis of inflammatory ureteral polyps.",[26],"Ureteral Calculi","RECRUITING","2026-06-04",{"date":30,"type":31},"2026-06-08","ACTUAL",{"date":33,"type":31},"2018-01-01",{"date":35,"type":22},"2027-02-01",{"name":37,"class":38},"The First Hospital of Jilin University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":39},"100616837","phase-4-comparison-of-mirabegron-and-tamsulosin-for-ureteral-stone-expulsion-100616837","NCT07310797","Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion","A Randomized Controlled Trial Comparing Mirabegron and Tamsulosin for Ureteral Stone Expulsion and Clinical Symptom Improvement","Inclusion Criteria:\n\n1. Age and Sex: Adult patients aged 18 to 75 years, inclusive of both males and females.\n2. Diagnosis: Unilateral ureteral stone confirmed by Computed Tomography (CT), Renal Sonography, or Kidney-Ureter-Bladder (KUB) radiography.\n3. Stone Characteristics: Stone size between 4 mm and 10 mm; located in the upper (proximal), middle, or lower (distal) ureter.\n4. Symptoms and Renal Function: Presence of renal colic or hematuria, with no severe renal insufficiency (eGFR \\> 60 mL\u002Fmin\u002F1.73m²).\n\nExclusion Criteria:\n\n1. Urinary tract infection (UTI).\n2. Multiple or bilateral ureteral stones.\n3. Ureteral stones not visible on KUB radiography (radiolucent stones).\n4. Pregnant or lactating women.\n5. Severe hydronephrosis.\n6. Renal insufficiency (defined as eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m² or Serum Creatinine \\> 2 mg\u002FdL).\n7. Uncontrolled hypertension or major cardiovascular disease.\n8. Patients who refuse Medical Expulsive Therapy (MET).","75 Years",{"count":49,"type":22},500,"INTERVENTIONAL",[52],"PHASE4","This randomized controlled trial compares the efficacy and safety of four treatment strategies for ureteral stone expulsion: Mirabegron alone, Tamsulosin alone, a combination of both, and standard conservative care. Participants diagnosed with ureteral stones will be randomly assigned to one of these four groups. The primary objective is to evaluate the stone expulsion rate within 4 weeks. The study also assesses time to expulsion, pain intensity, analgesic use, and potential side effects.",[26],[56,57,58],"Mirabegron","Tamsulosin","Medical Expulsive Therapy",{"date":30,"type":31},{"date":61,"type":31},"2026-02-13",{"date":63,"type":22},"2030-12-31",{"name":65,"class":38},"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":50,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100638175","comfij-versus-conventional-double-j-stent-for-ureteral-stent-symptoms-100638175","NCT07627828","ComfiJ Versus Conventional Double-J Stent for Ureteral Stent Symptoms","Evaluation of Stent-Related Symptoms After ComfiJ Ureteric Stent Versus Conventional Double-J Ureteric Stent: A Prospective Multicenter Randomized Controlled Trial","COMFIJ-DJS","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Adult patients undergoing unilateral ureteroscopy or retrograde intrarenal surgery for ureteric or renal stones.\n* Intraoperative confirmation that short-term postoperative ureteric stenting for approximately 2 weeks is clinically indicated.\n* Indications for postoperative stenting may include ureteric edema, minor ureteric mucosal trauma, need for ureteric dilatation, ureteral access sheath use with expected postoperative edema, impacted stone, residual dust or fragments requiring temporary drainage, or prolonged procedure.\n* Ability to understand and complete the Arabic Ureteral Stent Symptom Questionnaire.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Cases in which no postoperative ureteric stent is clinically indicated.\n* Cases requiring prolonged urinary drainage or major reconstructive decision-making.\n* Bilateral ureteroscopy or retrograde intrarenal surgery.\n* Solitary kidney.\n* Major ureteric injury or ureteric perforation.\n* Preoperative febrile urinary tract infection or sepsis.\n* Pregnancy or breastfeeding.\n* Neurogenic bladder.\n* Overactive bladder syndrome.\n* Major neurological disease or psychiatric disease affecting symptom reporting.\n* History of major bladder, prostate, or pelvic surgery likely to confound stent-related symptoms.\n* Concomitant use of alpha-blockers, anticholinergics, chronic analgesics, or other medications likely to alter symptom evaluation.\n* Other acute medical conditions that might influence the Ureteral Stent Symptom Questionnaire pain score, including acute pancreatitis, acute gastroenteritis, or musculoskeletal disorders.\n* Known allergy to any study-related medication or device material.\n* Inability to comply with the follow-up schedule.",{"count":75,"type":22},150,[77],"NA","This prospective multicenter randomized controlled trial will compare stent-related symptoms after placement of a ComfiJ ureteral stent versus a conventional double-J ureteral stent in adult patients undergoing unilateral ureteroscopy or retrograde intrarenal surgery for urinary stones when short-term postoperative ureteral stenting is clinically indicated. Eligible patients will be randomized intraoperatively after the operating surgeon confirms the need for postoperative stenting. The primary outcome will be the Ureteral Stent Symptom Questionnaire urinary symptoms domain score on postoperative day 14 before planned stent removal.",[80,26,81],"Ureteral Stent-Related Symptoms","Urolithiasis",[83,84,85,86],"ComfiJ ureteral stent","Conventional double-J ureteral stent","Ureteral Stent Symptom Questionnaire","Ureteroscopy","2026-05-30",{"date":28,"type":31},{"date":90,"type":31},"2026-05-02",{"date":92,"type":22},"2027-05",{"name":94,"class":38},"Beni-Suef University",3,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":50,"phases":105,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":39},"100639013","phase-2-intravesical-aminophylline-for-urgent-ureteral-stenting-in-acute-calculous-anuria-100639013","NCT07617948","Intravesical Aminophylline for Urgent Ureteral Stenting in Acute Calculous Anuria","Intravesical Aminophylline-Assisted Urgent Retrograde Ureteral Stenting for Acute Calculous Anuria: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients aged 18 years or older.\n2. Diagnosis of acute calculous anuria due to ureteral stone obstruction in a solitary functioning kidney.\n3. Obstruction confirmed by pelvi-abdominal ultrasound and computed tomography of the urinary tract.\n4. Clinical and laboratory evidence of acute renal impairment, including oliguria or anuria and serum creatinine \\>2 mg\u002FdL.\n5. Ability to provide written informed consent.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to aminophylline, theophylline, or other methylxanthines.\n2. Evidence of active urinary tract infection or urosepsis.\n3. Previous history of ureteral stricture or major urinary tract reconstructive surgery.\n4. Hemodynamic instability requiring immediate life-saving measures before urological intervention.\n5. Pregnancy.",{"count":104,"type":22},72,[106],"PHASE2","Acute calculous anuria is a urological emergency caused by ureteral stone obstruction in a solitary functioning kidney or bilateral ureteral obstruction. Urgent decompression of the upper urinary tract is required to restore urine drainage and prevent further renal impairment.\n\nThis prospective randomized double-blind controlled trial will evaluate whether intravesical aminophylline can facilitate urgent retrograde ureteral stenting in adult patients with acute calculous anuria due to ureteral stones. Eligible patients will be randomly assigned to receive either intravesical aminophylline diluted in normal saline or placebo saline before attempted retrograde Double-J ureteral stent placement.\n\nThe primary outcome is technical success, defined as successful placement of a Double-J ureteral stent across the obstructing stone without the need for percutaneous nephrostomy. Secondary outcomes include stenting time, intraoperative complications, renal function recovery, postoperative pain, analgesic requirement, and the need for alternative drainage.",[109,26,110,111],"Acute Calculous Anuria","Obstructive Uropathy","Acute Kidney Injury",[113,114,115,116,117],"Intravesical aminophylline","Retrograde ureteral stenting","Acute calculous anuria","Emergency urinary drainage","Double-J stent","2026-05-29",{"date":120,"type":31},"2026-06-02",{"date":122,"type":31},"2026-04-08",{"date":124,"type":22},"2027-04",{"name":94,"class":38},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":50,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":150,"locationsCount":39},"100637967","phase-2-melatonin-and-solifenacin-for-double-j-ureteral-stent-symptoms-100637967","NCT07617922","Melatonin and Solifenacin for Double-J Ureteral Stent Symptoms","Melatonin Versus Solifenacin Versus Their Combination for Improving Double-J Ureteral Stent-Related Symptoms and Quality of Life: A Prospective Randomized Study","MEL-SOL-STENT","Inclusion Criteria:\n\n1. Age 18 to 60 years.\n2. Patients undergoing unilateral ureteroscopy or ureteroscopic lithotripsy with insertion of a unilateral Double-J ureteral stent.\n3. Ability to understand and complete the study questionnaires.\n4. Willingness to participate and provide written informed consent.\n\nExclusion Criteria:\n\n1. Bilateral ureteral stents.\n2. Stents inserted for malignant ureteral obstruction or non-stone reconstructive indications.\n3. Known hypersensitivity or contraindication to solifenacin or melatonin.\n4. History of acute or chronic urinary retention, or evidence of clinically significant bladder outlet obstruction at baseline.\n5. History of narrow-angle glaucoma or other contraindications to antimuscarinic therapy, including gastric retention.\n6. Significant hepatic impairment.\n7. Severe renal impairment if judged clinically relevant to study medication safety.\n8. Pre-existing moderate to severe lower urinary tract symptoms unrelated to the stent.\n9. Recent use of antimuscarinics, alpha-blockers, or melatonin that may interfere with symptom assessment.\n10. Pregnancy or lactation.\n11. Inability to complete follow-up.","60 Years",{"count":136,"type":22},189,[106],"Double-J ureteral stents are commonly inserted after ureteroscopy, but they may cause bothersome urinary symptoms, pain, sleep disturbance, and reduced quality of life.\n\nThis prospective randomized assessor-blinded three-arm clinical trial will compare oral solifenacin, oral melatonin, and their combination for improving ureteral stent-related symptoms in adult patients after unilateral ureteroscopic lithotripsy with insertion of a unilateral Double-J ureteral stent.\n\nParticipants will be randomized to receive solifenacin 5 mg once daily, melatonin 3 mg once nightly, or combined solifenacin 5 mg once daily plus melatonin 3 mg once nightly for 14 days after surgery. The primary outcome is the total Ureteral Stent Symptom Questionnaire score at postoperative Day 7. Secondary outcomes include total Ureteral Stent Symptom Questionnaire score at Day 14, change in questionnaire score between Day 7 and Day 14, Insomnia Severity Index score, Visual Analogue Scale pain score, adverse events, treatment compliance, and rescue analgesic consumption.",[80,26,140],"Lower Urinary Tract Symptoms",[142,143,85,144,145],"Double-J ureteral stent","Ureteral stent symptoms","Solifenacin","Melatonin",{"date":120,"type":31},{"date":148,"type":31},"2026-05-07",{"date":92,"type":22},{"name":94,"class":38},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":158,"maxAge":18,"enrollmentInfo":159,"targetDuration":4,"studyType":50,"phases":161,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":178,"locationsCount":39},"100640931","phase-2-intravesical-aminophylline-to-facilitate-ureteroscopic-access-in-children-with-distal-ureteral-stones-100640931","NCT07617896","Intravesical Aminophylline to Facilitate Ureteroscopic Access in Children With Distal Ureteral Stones.","Intravesical Aminophylline to Facilitate Semi-Rigid Ureteroscopic Access in Children With Lower Ureteral Stones: A Prospective Randomized Double-Blind Placebo-Controlled Trial","Inclusion Criteria:\n\n* Children older than 2 years and younger than 18 years.\n* Single unilateral lower\u002Fdistal ureteral stone confirmed by low-dose non-contrast computed tomography according to local policy.\n* Stone size 5 to 15 mm.\n* Candidate for definitive treatment by semi-rigid ureteroscopy.\n* Sterile urine culture before surgery, or previously positive urine culture that has been properly treated before intervention.\n* Intraoperative failed initial gentle negotiation of the ureteric orifice\u002Fintramural ureter according to the study definition.\n* Written informed consent from the parent or legal guardian, with child assent when appropriate.\n\nExclusion Criteria:\n\n* Known hypersensitivity to aminophylline, theophylline, or ethylenediamine.\n* Use of oral or intravenous aminophylline or theophylline within the previous 24 hours.\n* Pre-existing ipsilateral JJ ureteral stent.\n* Stone peeping at the ureteric orifice.\n* Congenital or acquired abnormality that may affect distal ureteric access, such as ureterocele, obstructive megaureter, distal ureteric stricture, previous ureteric reimplantation, or previous ipsilateral ureteral reconstruction.\n* Known bladder dysfunction or conditions likely to affect normal bladder capacity.\n* Multiple ipsilateral ureteral stones or associated renal stones requiring flexible ureteroscopy or a ureteral access sheath strategy.\n* Febrile urinary tract infection, pyonephrosis, sepsis, or any case requiring urgent decompression instead of definitive ureteroscopy.\n* Cardiac disease, arrhythmia, uncontrolled hypertension, hyperthyroidism, epilepsy or seizure disorder, or significant hepatic impairment.\n* Inability to complete follow-up.","2 Years",{"count":160,"type":22},60,[106],"This study will evaluate whether intravesical aminophylline can facilitate semi-rigid ureteroscopic access in children with distal ureteral stones when the first gentle attempt to enter the ureter is unsuccessful.\n\nChildren scheduled for semi-rigid ureteroscopy for distal ureteral stones will first undergo the standard gentle attempt to pass the ureteroscope through the ureteric orifice and intramural ureter. If access is achieved, the child will continue standard treatment and will not be randomized. If access is not achieved, the child will be randomized during the operation to receive either intravesical aminophylline or intravesical normal saline placebo.\n\nThe study solution will be instilled into the bladder for approximately 5 minutes, then drained, and a second gentle ureteroscopic access attempt will be made. The main outcome is successful same-session passage of the intended semi-rigid ureteroscope without balloon dilation. The study will also assess the need for JJ stenting and deferred ureteroscopy, same-session stone treatment, operative outcomes, complications, and early aminophylline-related safety.",[164,165,26],"Pediatric Urolithiasis","Distal Ureteral Stone",[167,168,169,170,171],"Intravesical Aminophylline","Semi-Rigid Ureteroscopy","Pediatric Ureteroscopy","Ureteroscopic Access","Distal Ureteral Stones","2026-05-25",{"date":174,"type":31},"2026-06-01",{"date":176,"type":31},"2026-05-09",{"date":92,"type":22},{"name":94,"class":38},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":186,"targetDuration":4,"studyType":50,"phases":188,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":39},"100637394","phase-2-l-citrulline-versus-tamsulosin-for-medical-expulsive-therapy-of-distal-ureteral-stones-100637394","NCT07617909","L-Citrulline Versus Tamsulosin for Medical Expulsive Therapy of Distal Ureteral Stones","L-Citrulline Versus Tamsulosin for Medical Expulsive Therapy of Distal Ureteral Stones: A Prospective Randomized Study","Inclusion Criteria:\n\n* Adults aged 18 to 60 years.\n* Single distal ureteral stone.\n* Stone size 5 to 10 mm.\n* Normal renal function.\n* Controlled pain.\n* Willingness to comply with follow-up for 4 weeks.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Fever or active urinary tract infection.\n* Severe hydronephrosis.\n* Solitary kidney.\n* Pregnancy.\n* Previous ureteric surgery.\n* Multiple ureteral stones.\n* Indication for urgent surgical intervention.\n* Known hypersensitivity or contraindication to L-citrulline or tamsulosin.\n* Inability to complete follow-up.",{"count":187,"type":22},120,[106],"This study will compare L-citrulline and tamsulosin as medical expulsive therapy for adults with single distal ureteral stones.\n\nEligible participants with a single distal ureteral stone measuring 5 to 10 mm will be randomly assigned to receive either oral L-citrulline 750 mg twice daily or oral tamsulosin 0.4 mg once daily. Treatment will continue until documented stone passage or completion of 4 weeks of therapy, whichever occurs first.\n\nParticipants will be followed weekly for up to 4 weeks. The main outcome is stone expulsion within 4 weeks. The study will also assess time to stone expulsion, pain episodes, analgesic use, need for additional intervention, and adverse events.",[165,81,26],[192,58,193,57],"L-Citrulline","Ureteral Stone Passage",{"date":174,"type":31},{"date":196,"type":31},"2026-05-06",{"date":198,"type":22},"2026-11",{"name":94,"class":38},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":50,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":222},"100352776","intraoperative-assessment-of-of-burst-wave-lithotripsy-bwl-100352776","NCT03873259","Intraoperative Assessment of of Burst Wave Lithotripsy (BWL)","Burst Wave Lithotripsy (BWL) for the Comminution of Urinary Tract Stones: Intraoperative Evaluation of Safety and Effectiveness","Inclusion Criteria:\n\n* Individuals presenting with at least one kidney stone apparent on CT\n* Individuals scheduled for clinical stone removal via ureteroscopy (URS)\n\nExclusion Criteria:\n\n* Individuals under 18 years of age\n* Individuals belonging to a vulnerable group (pregnant, mentally disabled, prisoner, etc.)\n* Individuals with uncorrected bleeding disorders or coagulopathies\n* Individuals taking a clinically significant anticoagulant dose at the time of the procedure\n* Individuals with a calcified abdominal aortic aneurysm or calcified renal artery aneurysm\n* Individuals with a solitary kidney\n* Individuals with a comorbidity risks which, at the discretion of the physician, would make the patient a poor candidate for the BWL procedure",{"count":208,"type":22},40,[77],"Burst Wave Lithotripsy (BWL) is a novel method of urinary stone fragmentation that uses multi-cycle bursts of low amplitude ultrasound to induce stone fracture. This is in contrast to traditional extracorporeal shock wave lithotripsy (SWL), which employs a brief single compression\u002Ftensile cycle of high amplitude (shock) waves to achieve stone fracture. This is a single-arm feasibility study to test the ability of BWL to comminute (fragment) stones in humans.",[212,26],"Renal Calculi","2026-05-10",{"date":215,"type":31},"2026-05-13",{"date":217,"type":31},"2019-08-08",{"date":219,"type":22},"2028-04-30",{"name":221,"class":38},"University of Washington",2,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":240,"leadSponsor":242,"locationsCount":4},"100636130","ursl-angle-for-predicting-intraoperative-conversion-100636130","NCT07561684","URSL Angle for Predicting Intraoperative Conversion","An Exploratory Predictive Study on the Intraoperative Change of Surgical Methods in Transurethral Ureteroscopy for Ureteral Calculi","URSL-PREDICT","Inclusion Criteria:\n\n1. Age \\> 18 years at the time of surgery, without restriction based on sex, ethnicity, or occupation.\n2. Preoperative imaging confirmation of unilateral, solitary, or unilateral multiple ureteral calculi. In cases of ipsilateral multiple stones, the calculus deemed primarily responsible for obstruction or designated as the principal surgical target shall serve as the index stone.\n3. Planned and attempted transurethral ureteroscopic lithotripsy as the initial treatment modality.\n4. Availability of preoperative thin-slice (section thickness ≤ 1.25 mm) computed tomography urography or non-contrast CT of the urinary tract in native Digital Imaging and Communications in Medicine (DICOM) format, of sufficient diagnostic quality to permit multiplanar reconstruction and precise morphometric analysis. Image data must be complete and free from substantial motion or beam-hardening artifact that would preclude accurate delineation of ureteral anatomy.\n\nExclusion Criteria:\n\n* 1.Absence of preoperative CT imaging performed at the participating institution; missing, corrupted, or irretrievable DICOM data; or suboptimal image quality that precludes reliable ureteral segmentation and measurement.\n\n  2.Incomplete inpatient medical records lacking essential demographic or baseline clinical data; operative notes containing insufficient procedural detail to definitively ascertain whether intraoperative conversion occurred or to adjudicate the specific etiology thereof.\n\n  3.Prior ipsilateral percutaneous nephrostomy tube placement or ureteral stent indwelling for any indication before the index URSL procedure.\n\n  4.Calculi situated at anatomically distinct locations, specifically the ureteropelvic junction or the ureteral orifice.\n\n  5.Antecedent ipsilateral ureteral surgery (e.g., ureteral reimplantation, prior ureteroscopic lithotripsy) or history of urinary diversion (e.g., ileal conduit). Such patients are excluded because surgical alteration of native ureteral anatomy would confound the morphometric assumptions underlying URSL angle determination.",{"count":232,"type":22},2200,"This international multicenter retrospective cohort study aims to externally validate the URSL Predictive Angle, a novel CT-derived morphometric parameter, as an imaging biomarker for predicting intraoperative conversion risk during transurethral ureteroscopic lithotripsy (URSL) for ureteral calculi.\n\nIntraoperative conversion is defined as the unanticipated abandonment of the planned endoscopic approach due to unfavorable ureteral anatomy or stone impaction, necessitating recourse to open ureterolithotomy, laparoscopic ureterolithotomy, or ureteral stent placement with planned staged secondary intervention. Such conversions are associated with protracted operative duration, heightened anesthetic exposure, and increased physical, psychological, and financial burdens on patients.\n\nThe URSL Predictive Angle is a geometric parameter derived from preoperative coronal CT reformations that quantifies the degree of local ureteral angulation induced by an impacted calculus. Preliminary single-center data demonstrated robust predictive fidelity of this metric with an area under the ROC curve of 0.861 and an optimal discriminatory threshold of 131.8° yielding a sensitivity of 82% and a specificity of 88%.\n\nThis study will enroll eligible patients from multiple domestic and international tertiary care hospitals who underwent URSL for ureteral calculi between January 1, 2018, and December 31, 2025. The primary outcome is intraoperative conversion of surgical approach. The predictive performance of the URSL angle will be evaluated using ROC curve analysis with AUC calculation. Propensity score matching and multivariable logistic regression will be employed to address potential confounding.\n\nThis study is registered as a patient registry with a cohort model. Data collection is retrospective, involving abstraction from electronic medical records, operative logs, and PACS. A waiver of informed consent has been requested based on the retrospective design, minimal risk determination, stringent anonymization procedures, and impracticability of obtaining individual consent.",[26],"NOT_YET_RECRUITING","2026-04-24",{"date":238,"type":31},"2026-05-01",{"date":174,"type":22},{"date":241,"type":22},"2026-09-30",{"name":37,"class":38},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":250,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":4},"100596278","impact-of-humid-heat-on-gut-tryptophan-stone-pathway-100596278","NCT07043374","Impact of Humid-Heat on Gut-Tryptophan-Stone Pathway","A Mechanistic Study on How Humid and Hot Environment Promotes Urinary Tract Stone Formation Through Influencing Gut Microbiota and Tryptophan Metabolism","Inclusion Criteria:\n\n* Inclusion criteria for patients with kidney stones\n\n  * Age\\>=18 years;\n  * Diagnosed with kidney stones by ultrasound, CT or urography;\n  * Willing to provide stool samples and serum samples for study;\n  * No history of antimicrobial use in the past 3 months;\n  * Signed and dated informed consent indicating that the patient or his\u002Fher legal representative is fully informed of the study-related information and agrees to participate.\n* Inclusion criteria for the healthy control group\n\n  * Age\\>=18 years;\n  * No history of kidney stones and family history;\n  * Imaging examination (such as abdominal ultrasound) showed no kidney stones;\n  * Willing to provide stool samples and serum samples for research;\n  * No history of antibiotic use in the past 3 months;\n  * Signed and dated informed consent indicating that the volunteer is fully informed about the study-related information and agrees to participate.\n\nExclusion Criteria:\n\n* Use of antimicrobials or probiotics within the past 3 months;\n* Presence of active urinary tract infection;\n* Presence of other serious systemic diseases, such as hepatic or renal insufficiency, cardiac or pulmonary diseases, malignant tumors, and immunodeficiency states;\n* Congenital urinary tract abnormalities;\n* Previous history of kidney transplantation or urinary diversion surgery;\n* Pregnant or lactating women;\n* Presence of chronic intestinal diseases, such as inflammatory bowel disease, irritable bowel syndrome, etc.;\n* Inability to provide samples or complete follow-up according to the research protocol;\n* Participation in other clinical studies within the past 3 months;\n* Other conditions deemed unsuitable for participation in this study by the researcher.",true,{"count":252,"type":22},270,"Investigating the differences in gut microbiota composition and tryptophan metabolite levels between kidney stone patients and healthy individuals, with special focus on:\n\n1. Comparing the gut microbiota composition between kidney stone patients and healthy controls, with emphasis on analyzing the relative abundance of Lactobacillus salivarius\n2. Comparing the differences in tryptophan metabolite levels such as indole-3-carboxylic acid (ICA) and kynurenine (Kyn) in serum between the two groups\n3. Exploring the correlation between gut microbiota composition and tryptophan metabolite levels\n4. Analyzing the influence of different environmental conditions (seasons, temperature and humidity) on gut microbiota and metabolite levels",[255,26],"Kidney Calculi","2026-01-18",{"date":258,"type":31},"2026-01-21",{"date":260,"type":22},"2026-09-01",{"date":262,"type":22},"2027-12-31",{"name":264,"class":38},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":4},"100567382","new-laser-and-suction-sheath-for-kidney-stone-treatment-100567382","NCT06667466","New Laser and Suction Sheath for Kidney Stone Treatment","Prospective, Multicenter, Randomized Controlled Trial of Super Pulse Thulium Fiber Laser Combined With Flexible Negative Pressure Suction Sheath Versus Conventional Sheath for the Treatment of Kidney Stones","Inclusion Criteria:\n\n* Age ≥18 years old.\n* Diagnosed with kidney stones and\u002For ureteral stones, and stone diameter is ≥6mm and ≤20mm\n* Plan to undergo fURS lithotripsy\n* General anesthesia to complete the operation\n* The latest urine culture before surgery is negative\n* Signed and dated informed consent\n\nExclusion Criteria:\n\n* Isolated kidney\n* Previous history of kidney transplantation or urinary diversion surgery\n* Congenital malformations of urinary system\n* Abnormal coagulation mechanism due to blood system diseases, liver diseases, etc\n* Severe heart or lung disease, malignancy and immune deficiency status\n* Neurogenic bladder\n* Failure to provide informed consent\n* Have an untreated urinary tract infection\n* The presence of known anatomic abnormalities (such as ureteral stenosis), urothelial tumors, or stones that can be removed directly without the use of laser lithotripsy\n* Pregnant women\n* In cases where the stone cannot be reached with a bendable negative pressure suction sheath, or in cases where the stone cannot be reached with a conventional sheath or the pyeloureteral junction\n* Epidural anesthesia or lumbar anesthesia to complete the operation","70 Years",{"count":274,"type":22},140,"The goal of this clinical trial is to learn if the combination of super pulsed thulium fiber laser (sTFL) with a flexible negative pressure suction sheath is more effective and safer than sTFL with a conventional sheath in treating kidney stones and\u002For ureteral stones. The main questions it aims to answer are:\n\nDoes the sTFL with a flexible negative pressure suction sheath have a higher stone - free rate than the sTFL with a conventional sheath? Does the sTFL with a flexible negative pressure suction sheath have fewer complications than the sTFL with a conventional sheath?\n\nResearchers will compare the two treatment groups to see if there are differences in stone - free rate and complication rates.\n\nParticipants will:\n\nUndergo ureteroscopic lithotripsy surgery. In the experimental group, have a flexible negative pressure suction sheath inserted along a guidewire to the stone site under general anesthesia, then have a ureteroscope inserted through the sheath to the stone site, and have the stone fragmented by sTFL with a power setting of 0.8J and a frequency of 12 - 20Hz while the fragments are removed by negative pressure suction.\n\nIn the control group, have a conventional sheath inserted to the upper ureter or the ureteropelvic junction under general anesthesia, then have a ureteroscope inserted through the sheath to the stone site, and have the stone fragmented by sTFL with a power setting of 0.8J and a frequency of 12 - 20Hz and the fragments removed by a stone basket.",[255,26],{"date":258,"type":31},{"date":279,"type":22},"2026-11-20",{"date":281,"type":22},"2027-11-20",{"name":264,"class":38}]